Design, synthesis and biological activity of beta-carboline-based type-5 phosphodiesterase inhibitors.

[1]  C. Stief,et al.  Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle , 2005, World Journal of Urology.

[2]  J. Jankovic,et al.  Dopamine agonists in Parkinson’s disease , 2003, Expert opinion on investigational drugs.

[3]  A. Stamford.  Chapter 6. Phosphodiesterase 5 inhibitors , 2002 .

[4]  J. Beavo,et al.  Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  G. Maw.  Chapter 8. Pharmacological Therapy for the Treatment of Erectile Dysfunction , 1999 .

[6]  S. Ballard,et al.  Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. , 1998, The Journal of urology.

[7]  I. Eardley.  New oral therapies for the treatment of erectile dysfunction. , 1998, British journal of urology.

[8]  I. Eardley.  The role of phosphodiesterase inhibitors in impotence. , 1997, Expert opinion on investigational drugs.

[9]  A. Burnett.  Nitric oxide in the penis: physiology and pathology. , 1997, The Journal of urology.

[10]  Andrew Simon Bell,et al.  Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction , 1996 .

[11]  J. Beavo,et al.  Multiple cyclic nucleotide phosphodiesterases. , 1994, Molecular pharmacology.

[12]  A. Melman,et al.  A review of erectile dysfunction: new insights and more questions. , 1993, The Journal of urology.